BG Medicine (OTCMKTS:BGMD) & Oruka Therapeutics (NASDAQ:ORKA) Financial Review

BG Medicine (OTCMKTS:BGMD) and Oruka Therapeutics (NASDAQ:ORKA) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, analyst recommendations, profitability, institutional ownership and risk.

Analyst Ratings

This is a breakdown of recent ratings and target prices for BG Medicine and Oruka Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BG Medicine	0	0	0	0	0.00
Oruka Therapeutics	0	0	7	1	3.13

Oruka Therapeutics has a consensus price target of $43.17, suggesting a potential upside of 127.07%. Given Oruka Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Oruka Therapeutics is more favorable than BG Medicine.

Insider & Institutional Ownership

56.4% of Oruka Therapeutics shares are owned by institutional investors. 6.5% of BG Medicine shares are owned by company insiders. Comparatively, 22.7% of Oruka Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares BG Medicine and Oruka Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BG Medicine	N/A	N/A	N/A	N/A	N/A
Oruka Therapeutics	N/A	N/A	-$5.34 million	($6.26)	-3.04

Profitability

This table compares BG Medicine and Oruka Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BG Medicine	N/A	N/A	N/A
Oruka Therapeutics	N/A	-24.96%	-21.22%

Risk and Volatility

BG Medicine has a beta of 0.63, suggesting that its share price is 37% less volatile than the S&P 500. Comparatively, Oruka Therapeutics has a beta of 0.78, suggesting that its share price is 22% less volatile than the S&P 500.

Summary

Oruka Therapeutics beats BG Medicine on 7 of the 9 factors compared between the two stocks.

About BG Medicine

BG Medicine, Inc. engages in the development and commercialization of diagnostic products used to guide the patients suffering from heart failure and related disorders in the United States. The company offers BGM Galectin-3 Test, an in vitro diagnostic device that measures galectin-3 in serum or plasma by enzyme linked immunosorbent assay on a microtiter plate platform; and CardioSCORE Test, a multi-analyte biomarker-based blood test used for the assessment of near-term risk of atherothrombotic cardiovascular events, such as heart attack and ischemic stroke. It has license, development, and commercialization agreements with Abbott Laboratories, bioMérieux SA, Siemens Healthcare Diagnostics Inc., and Alere Inc. for the automated instrument versions of galectin-3 test; and a strategic collaboration with Abbott Laboratories to develop and commercialize galectin-3 assay kits, and related control kits and calibrators. The company was formerly known as Beyond Genomics, Inc. and changed its name to BG Medicine, Inc. in October 2004. BG Medicine, Inc. was founded in 2000 and is headquartered in Waltham, Massachusetts.

About Oruka Therapeutics

ARCA biopharma, Inc., a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products. The Company’s business focus combines expertise in cardiovascular pathophysiology, molecular genetics, clinical development and product commercialization. It is currently developing Gencaro (bucindolol hydrochloride), a cardiovascular drug for the treatment of chronic heart failure. The company is based in Broomfield, Colorado.